Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan:24 Suppl 1:63-74.
doi: 10.1111/dom.14713. Epub 2022 Apr 25.

Rapid-acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes

Christophe E M De Block  1   2 , Jolijn Van Cauwenberghe  1   2 , Niels Bochanen  1   2 , Eveline Dirinck  1   2
Affiliations
Review

Rapid-acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes

Christophe E M De Block et al. Diabetes Obes Metab. 2022 Jan.

Abstract

Since the discovery of insulin 100 years ago, insulin preparations have improved significantly. Starting from purified animal insulins, evolving to human insulins produced by genetically modified organisms, and ultimately to insulin analogues, all in an attempt to mimic physiological insulin action profiles seen in individuals without diabetes. Achieving strict glucose control without hypoglycaemia and preventing chronic complications of diabetes while preserving quality of life remains a challenging goal, but the advent of newer ultra-rapid-acting insulin analogues may enable intensive insulin therapy without being too disruptive to daily life. Ultra-rapid-acting insulin analogues can be administered shortly before meals and give better coverage of mealtime-induced glucose excursions than conventional insulin preparations. They also increase convenience with timing of bolus dosing. In this review, we focus on the progress that has been made in rapid-acting insulins. We summarize pharmacokinetic and pharmacodynamic data, clinical trial data supporting the use of these new formulations as part of a basal-bolus regimen and continuous subcutaneous insulin infusion, and provide a clinical perspective to help guide healthcare professionals when and for whom to use ultra-fast-acting insulins.

Keywords: rapid-acting insulin analogue; ultra-rapid-acting insulin.

PubMed Disclaimer

References

REFERENCES

    1. Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions, version 6.1 (updated September 2020). Oxford, UK: Cochrane Collaboration and John Wiley & Sons; 2020.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
    1. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
    1. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16.
    1. Brange J, Havelund S, Hommel E, Sørensen E, Kühl C. Neutral insulin solutions physically stabilized by addition of Zn2+. Diabet Med. 1986;3:532-536.

LinkOut - more resources